PE anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_GK1dot5_PE_021706
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE (filled histogram) or rat IgG2b, κ PE isotype control (open histogram).
  • 1_GK1dot5_PE_021706
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE (filled histogram) or rat IgG2b, κ PE isotype control (open histogram).
  • 2_GK15_PE_CD4_Antibody_2_040122
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE (solid line) or rat IgG2b, κ PE isotype control (dashed line).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
100407 50 µg 20€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100408 200 µg 58€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Ajith A, et al. 2021. Front Immunol. 12:687715. PubMed
  2. Garo LP, et al. 2021. Nat Commun. 12:2419. PubMed
  3. Apte SH, et al. 2020. Clin Transl Immunology. 9:e1209. PubMed
  4. Friess MC, et al. 2022. Cell Rep. 38:110334. PubMed
  5. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  6. Kawai H, et al. 2021. Asian Pac J Allergy Immunol. :. PubMed
  7. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  8. Palacios-Arreola M, et al. 2017. Sci Rep. 10.1038/s41598-017-10135-1. PubMed
  9. Man SM et al. 2016. Cell. 167(2):382-396 . PubMed
  10. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  11. Xu X, et al. 2020. Chin Med. 15:33. PubMed
  12. Kisielow J, et al. 2019. Nat Immunol. 1.286111111. PubMed
  13. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  14. Feola S, et al. 2022. Front Immunol. 13:826164. PubMed
  15. Zhao X, et al. 2022. Front Mol Biosci. 9:786864. PubMed
  16. Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed
  17. Chappaz S, et al. 2021. Cell Reports. 36(3):109430. PubMed
  18. Han X, et al. 2017. Int J Mol Sci. 10.3390/ijms18050942. PubMed
  19. Willinger T, et al. 2014. J Exp Med. 211:685. PubMed
  20. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
  21. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  22. Bauer KM, et al. 2022. JCI Insight. 7:. PubMed
  23. Zhang L, et al. 2020. Front Oncol. 1.243055556. PubMed
  24. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  25. Du Q, et al. 2019. Front Microbiol. 10:2050. PubMed
  26. Tan X, et al. 2021. Front Oncol. 11:768222. PubMed
  27. Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
  28. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  29. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  30. Hao B, et al. 2015. J Exp Med. 212:809. PubMed
  31. Sun CC, et al. 2020. Genome Med. 0.553472222. PubMed
  32. Leech JM, et al. 2020. Cell Host & Microbe. 26(6):795-809.e5.. PubMed
  33. Isoda T et al. 2017. Cell. 171(1):103-119 . PubMed
  34. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  35. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  36. Chen S et al. 2018. Cell reports. 25(7):1729-1740 . PubMed
  37. Pérez‐Mazliah D et al. 2017. EBioMedicine. 24:216-230 . PubMed
  38. Yuan X, et al. 2019. JCI Insight. 4:e124317. PubMed
  39. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  40. Guo H, et al. 2022. PLoS Pathog. 18:e1010857. PubMed
  41. Khan IM, et al. 2021. Immunohorizons. 5:703. PubMed
  42. Antunes KH, et al. 2022. Front Immunol. 13:867022. PubMed
  43. Li Y, et al. 2022. Clin Transl Immunology. 11:e1362. PubMed
  44. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  45. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  46. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  47. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  48. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  49. Sato K, et al. 2015. PLoS One. 10: 0138291. PubMed
  50. Liu J, et al. 2012. PLoS One. 7:e44044. PubMed
  51. Lercher A, et al. 2019. Immunity. 51:1074. PubMed
  52. Pereira JL, et al. 2021. Transl Oncol. 14:101125. PubMed
  53. Collin R, et al. 2014. J Immunol. 193:3503. PubMed
  54. Karki R, et al. 2020. JCI Insight. 5:00. PubMed
  55. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  56. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  57. Hillel–Karniel C, et al. 2020. Cell Reports. 30(3):807-819.e4.. PubMed
  58. Yang L, et al. 2021. Cell Death Differ. 28:2616. PubMed
  59. Pervaiz N, et al. 2021. Pigment Cell Melanoma Res. 34:918. PubMed
  60. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  61. Li J, et al. 2021. Cell Commun Signal. 19:89. PubMed
  62. Lv F, et al. 2022. iScience. 25:103639. PubMed
  63. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  64. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  65. Fatkhullina AR et al. 2018. Immunity. 49(5):943-957 . PubMed
  66. Huang YL, et al. 2021. Commun Biol. 4:229. PubMed
  67. Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed
  68. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  69. Yang H, et al. 2022. Nutrients. 14:. PubMed
  70. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  71. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  72. Hönes J, et al. 2017. Sci Rep. . 10.1038/s41598-017-15866-9. PubMed
  73. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  74. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  75. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  76. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  77. Harnett MM, et al. 2022. Front Immunol. 13:953053. PubMed
  78. Shen X, et al. 2021. Front Immunol. 12:710750. PubMed
  79. Zuo W, et al. 2022. Cell Death Discov. 8:257. PubMed
  80. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  81. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  82. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  83. Yang C, et al. 2013. Proc Natl Acad Sci U S A. 111:109. PubMed
  84. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  85. Cheng Y, et al. 2020. PLoS Pathog. 16:e1008569. PubMed
  86. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  87. Bai C, et al. 2020. Mol Ther Oncolytics. 17:9. PubMed
  88. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  89. Dmitrieva‐Posocco O et al. 2019. Immunity. 50(1):166-180 . PubMed
  90. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  91. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  92. Liu W, et al. 2021. Cell Death Discov. 7:136. PubMed
  93. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  94. Cho K, et al. 2021. iScience. 24:103117. PubMed
  95. Wu H, et al. 2021. Cell Death Discov. 7:225. PubMed
  96. Colombo M, et al. 2022. iScience. 25:105042. PubMed
  97. Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed
  98. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  99. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  100. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  101. Cai Y, et al. 2019. Cell Rep. 27:3034. PubMed
  102. Matsuo K, et al. 2018. J Immunol. 200:800. PubMed
  103. Du J, et al. 2018. AMB Express. 8:158. PubMed
  104. Andrade ACDSP, et al. 2021. J Virol. 95:e0127621. PubMed
  105. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  106. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  107. Liyanage S, et al. 2016. Exp Eye Res. 151:160-70. PubMed
  108. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  109. Tomay F, et al. 2019. J Transl Med. 17:237. PubMed
  110. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  111. Zhong MC, et al. 2021. J Exp Med. 218:. PubMed
  112. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  113. Nakamura Y, et al. 2015. Infect Immun . 83:671. PubMed
  114. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  115. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  116. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  117. Rive CM, et al. 2022. Mol Ther Methods Clin Dev. 26:4. PubMed
  118. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  119. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  120. Ben-Yehuda H, et al. 2021. Mol Neurodegener. 16:39. PubMed
  121. Li X, et al. 2021. Cell Death Dis. 12:314. PubMed
  122. Bi CS, et al. 2020. Cell Prolif. 53:e12827. PubMed
  123. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  124. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  125. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  126. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  127. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  128. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  129. Zhang H, et al. 2009. Invest Ophthalmol Vis Sci. 50:2653. PubMed
  130. Chen S, et al. 2022. iScience. 25:105176. PubMed
  131. Georgiadou A, et al. 2022. Elife. 11:. PubMed
  132. Chen C, et al. 2020. Cell Rep. 2136:30. PubMed
  133. Sanders K, et al. 2015. Cancer Immunol Res. 3: 891-901. PubMed
  134. McCauley ME, et al. 2020. Nature. 585(7823):96-101. PubMed
  135. Liu Y, et al. 2019. Sci Rep. 9:18970. PubMed
  136. Wang J, et al. 2019. Aging (Albany NY). 11:3463. PubMed
  137. Rodríguez L, et al. 2021. Biomolecules. 11: . PubMed
  138. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  139. Pantelidou C, et al. 2022. NPJ Breast Cancer. 8:102. PubMed
  140. Deliyannis G, et al. 2021. JCI Insight. 6:. PubMed
  141. Le QV, et al. 2022. Bioact Mater. 15:160. PubMed
  142. Mahlios J, Zhuang Y 2011. Mol Immunol. 49:227. PubMed
  143. Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed
  144. Klose R, et al. 2016. Nat Commun. 7:12528. PubMed
  145. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  146. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  147. Ireland L, et al. 2020. Front Immunol. 11:297. PubMed
  148. Li H, et al. 2022. iScience. 25:104481. PubMed
  149. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  150. Endo-Umeda K, et al. 2021. Sci Rep. 11:22595. PubMed
  151. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  152. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  153. Gao P, et al. 2021. Nat Commun. 1194:12. PubMed
  154. Yomogida K, et al. 2013. Biochem Biophys Res Commun. 434:263. PubMed
  155. Ajith A, et al. 2019. FASEB J. 33:5220. PubMed
  156. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  157. Yeon S, et al. 2017. Sci Rep. 10.1038/s41598-017-11492-7. PubMed
  158. Hu Y, et al. 2021. J Nanobiotechnology. 19:416. PubMed
  159. Petty AJ, et al. 2021. JCI Insight. 6:. PubMed
  160. Gawish R, et al. 2022. Elife. 11:. PubMed
  161. Kong IY, et al. 2020. Cell Rep. 33:108290. PubMed
  162. Fu W, et al. 2020. J Immunol Res. 8820355:2020. PubMed
  163. Mesin L, et al. 2020. Cell. 180(1):92-106.e11.. PubMed
  164. Crowe J, et al. 2020. PLoS Pathog. 16:e1008391. PubMed
  165. Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed
  166. Rudd CE, et al. 2020. Cell Reports. 30(7):2075-2082. PubMed
  167. Cao Y, et al. 2022. Small. 18:e2203466. PubMed
  168. Xu Z, et al. 2022. Cell Death Dis. 13:502. PubMed
  169. Wang Y, et al. 2022. Nat Cell Biol. 24:230. PubMed
  170. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed
  171. Lee S, et al. 2021. Autophagy. Online ahead of print. PubMed
  172. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  173. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  174. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  175. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  176. Sun J, et al. 2012. Arterioscler Thromb Vasc Biol. 32:15:00. PubMed
RRID
AB_312692 (BioLegend Cat. No. 100407)
AB_312693 (BioLegend Cat. No. 100408)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC, IHC-F, ICC
FITC anti-mouse CD4 GK1.5 FC, IHC-F, ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC, IHC-F, ICC, IP, Costim, Block, Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC, IHC-F, ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC, IHC-F, ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC, ICC, IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC, Block, Costim, Depletion, IHC, IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F, FC, ICC, SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC, IHC-F, ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-mouse CD4

  • Biotin anti-mouse CD4

  • FITC anti-mouse CD4

  • PE anti-mouse CD4

  • PE/Cyanine5 anti-mouse CD4

  • Purified anti-mouse CD4

  • PE/Cyanine7 anti-mouse CD4

  • APC/Cyanine7 anti-mouse CD4

  • Alexa Fluor® 647 anti-mouse CD4

  • Alexa Fluor® 488 anti-mouse CD4

  • Pacific Blue™ anti-mouse CD4

  • Alexa Fluor® 700 anti-mouse CD4

  • PerCP anti-mouse CD4

  • PerCP/Cyanine5.5 anti-mouse CD4

  • Brilliant Violet 421™ anti-mouse CD4

  • Ultra-LEAF™ Purified anti-mouse CD4

  • Alexa Fluor® 594 anti-mouse CD4

  • Brilliant Violet 711™ anti-mouse CD4

  • Brilliant Violet 510™ anti-mouse CD4

  • Brilliant Violet 605™ anti-mouse CD4

  • Brilliant Violet 785™ anti-mouse CD4

  • PE/Dazzle™ 594 anti-mouse CD4

  • APC/Fire™ 750 anti-mouse CD4

  • GoInVivo™ Purified anti-mouse CD4

  • Brilliant Violet 750™ anti-mouse CD4

  • Brilliant Violet 650™ anti-mouse CD4

  • Spark Blue™ 550 anti-mouse CD4

  • Spark NIR™ 685 anti-mouse CD4

  • KIRAVIA Blue 520™ anti-mouse CD4

  • PE/Fire™ 640 anti-mouse CD4

  • APC/Fire™ 810 anti-mouse CD4

  • PE/Fire™ 700 anti-mouse CD4

  • Spark Violet™ 538 anti-mouse CD4

  • Spark YG™ 593 anti-mouse CD4

  • Spark Blue™ 574 anti-mouse CD4 Antibody

  • Spark UV™ 387 anti-mouse CD4

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account